Clinical trials
Recurrent or Metastatic Solid Tumors clinical trials
Below are recruiting recurrent or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 3,362 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06155396RecruitingPhase 2
Targeted drug combo for advanced cervical cancer
This trial tests a combination of two drugs: an antibody-drug conjugate (RC48-ADC) that targets HER2 on cancer cells, plus an immunotherapy (Zimberelimab) that helps your immune system attack the cancer. It is for people with advanced cervical cancer whose prior platinum-based chemotherapy has stopped working.
Bengbu, AnhuiAges 18 years+ - NCT06160596Recruiting
Understanding long-term cancer survival in hard-to-treat tumors
This study looks at why some people with hard-to-treat cancers live much longer than expected. It collects tumor samples to search for clues that might help future patients.
VillejuifAges 18 years+ - NCT06185556RecruitingPhase 2/Phase 3
New treatments for liver tumors near blood vessels or bile ducts
This trial tests two procedures—irreversible electroporation and stereotactic body radiotherapy—for people whose colorectal cancer has spread to the liver (1–3 tumors near major blood vessels or bile ducts) and can't be surgically removed or treated with heat. The goal is to see if these approaches can safely destroy those hard-to-reach tumors.
Amsterdam, North HollandAges 18 years+ - NCT06197776Recruiting
Predicting treatment success for advanced nasopharyngeal cancer
This study uses advanced testing (multi-omics) to predict if combining chemoradiation with immunotherapy works better for nasopharyngeal cancer that has returned or spread. It aims to find the right treatment for each person.
Guangzhou, GuangdongAges 18–70 - NCT06202261RecruitingPhase 1/Phase 2
Study of TQB2930 for breast cancer that has returned or spread
This trial tests a new drug called TQB2930 alone or with other treatments for people with recurrent or metastatic breast cancer. It may help if you have a type of breast cancer called HER2-positive and have not had many prior treatments for advanced disease.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT06224387RecruitingPhase 1/Phase 2
Study of a new drug for advanced solid tumors
This trial tests a new drug, CTS2190, for people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The goal is to see if the drug is safe and effective.
Luoyang, HenanAges 18 years+ - NCT06232122Recruiting
New PET scans to detect ovarian cancer recurrence
This study uses two types of PET/CT scans (68Ga-FAPI-46 and 18F-FDG) to look for any returning ovarian cancer. The goal is to find recurrence early so you and your doctor can plan the next steps.
Taoyuan CityAges 30–80 - NCT06239194RecruitingPhase 1/Phase 2
MdX2001 for advanced solid tumors
This trial tests a new drug, MDX2001, for people with advanced solid tumors that have spread. The study aims to find the best dose and see how well it works.
Denver, ColoradoAges 18 years+ - NCT06266338RecruitingPhase 2
Pembrolizumab and lenvatinib for recurrent or metastatic cervical cancer
This study tests a combination of two drugs, pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy), for people with cervical cancer that has come back or spread. The goal is to see if this drug combination can shrink tumors or slow the cancer's growth.
Dallas, TexasAges 18 years+ - NCT06279364RecruitingPhase 3
Testing SKB264 vs standard chemo for advanced triple-negative breast cancer
This trial tests a new drug called SKB264 against standard chemotherapy options for people with advanced triple-negative breast cancer who have not yet received chemotherapy for their advanced disease. The goal is to see if SKB264 works better than the usual treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06292689RecruitingPhase 2
Cardunolizumab for advanced vulvar or vaginal cancer
This study is testing a new drug called cardunolizumab for people with advanced vulvar or vaginal cancer that has come back or spread. The goal is to see if the drug can shrink tumors or slow the cancer's growth.
Hangzhou, ZhejiangAges 18–75 - NCT06311578RecruitingPhase 1
Study of JNJ-87704916 alone or with other drugs for advanced solid tumors
This trial tests a new drug, JNJ-87704916, given alone or with other treatments for people with advanced solid tumors that have stopped responding to standard therapies. It may be an option if you have a tumor that can be injected and are in good overall health.
New York, New YorkAges 18 years+ - NCT06324240RecruitingPhase 1
Personalized vaccine plus immunotherapy for triple-negative breast cancer
This trial tests a personalized vaccine made from your tumor combined with immunotherapy drugs (pembrolizumab or ipilimumab) for triple-negative breast cancer. It aims to help your immune system recognize and attack cancer cells.
Atlanta, GeorgiaAges 18 years+ - NCT07341737RecruitingPhase 1/Phase 2
SL-28 for advanced solid tumors that haven’t responded to treatment
This trial tests a new drug, SL-28, for people with advanced solid tumors that haven’t responded to or cannot be treated with standard therapies. It aims to find a safe dose and see if the drug can help shrink or slow the growth of your cancer.
Adelaide, South AustraliaAges 18 years+ - NCT07020117RecruitingPhase 1
Study of AKY-1189 for advanced solid tumors
This trial tests a new radioactive drug, AKY-1189, for people with solid tumors that have spread or cannot be removed. It may help if other treatments have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT06329570RecruitingPhase 1/Phase 2
Bevacizumab with focused ultrasound for recurrent glioblastoma
This trial tests whether adding a focused ultrasound system (NaviFUS) to the drug bevacizumab can help people whose glioblastoma has come back. The treatment aims to deliver the drug more precisely to the brain tumor and potentially improve outcomes.
Charlottesville, VirginiaAges 18 years+ - NCT06332755RecruitingPhase 1
Study of LB-LR1109 alone and with atezolizumab for cancer
This trial tests a new drug called LB-LR1109, alone or with atezolizumab, for adults with certain advanced solid tumors, including non-small cell lung cancer. It's for people whose cancer has worsened after standard treatments or who cannot have those treatments.
Fairfax, VirginiaAges 18 years+ - NCT06333314RecruitingPhase 2
Dostarlimab for advanced dMMR/MSI cancers (not colorectal or endometrial)
This trial tests a drug called dostarlimab for people with certain advanced cancers that have a specific genetic feature (dMMR/MSI-H). The goal is to see if it helps shrink or control the cancer in people who haven't had other treatments yet.
AngersAges 18 years+ - NCT06356272Recruiting
Oropharynx cancer biomarker study
This study looks at certain markers (called p16 and HPV) in tumor samples to better understand oropharynx cancer. It may help doctors learn more about the disease and guide future treatments.
Rochester, MinnesotaAges 18 years+ - NCT06367088RecruitingPhase 2
Combination drug therapy for advanced triple-negative breast cancer
This trial tests a new drug (cadonilimab) plus chemotherapy for people with advanced triple-negative breast cancer that has come back or spread. It aims to see if the combination works better than standard treatment.
Wuhan, HubeiAges 18–70 - NCT06385925RecruitingPhase 1/Phase 2
Study of TSN1611 for cancers with KRAS G12D mutation
This trial tests a new drug called TSN1611 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug can shrink tumors or stop them from growing.
Houston, TexasAges 18–75 - NCT06387628RecruitingPhase 2
LM-108 with immunotherapy for advanced triple-negative breast cancer
This trial tests a new drug called LM-108 combined with a PD-1 inhibitor (a type of immunotherapy) for people with triple-negative breast cancer that has come back or spread. It aims to see if this combination can help shrink tumors or slow the disease.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06413992RecruitingPhase 2
Camrelizumab plus fluzoparib for TP53-mutated endometrial cancer
This trial tests a combination of two drugs, camrelizumab (an immunotherapy) and fluzoparib (a PARP inhibitor), for people with a specific type of endometrial cancer that has a TP53 gene mutation. It may offer a new option for advanced or recurrent disease after limited prior treatment.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06427460RecruitingPhase 2
Focused radiation therapy for solid tumors
This trial tests a special type of radiation that delivers a higher dose to the center of the tumor while limiting radiation to nearby healthy organs. It's for people with certain solid tumors that haven't spread widely or have only a few metastases.
Shanghai, Shanghai MunicipalityAges 18–75
Hear when a new Recurrent or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic solid tumors?
- Yes. Clin2 currently lists 3,362 recruiting recurrent or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.